According to the most recent Harris Interactive poll the "Reputation of Pharmaceutical Companies, While Still Poor, Improves Sharply for Second Year in a Row."

The recovery is no fluke, but what could possibly be the cause of this reversal of fortune? Harris may be an excellent pollster, but its analysis of the causes of the reversal is shallow and weak (based on what I read in the press release). I, on the other hand, draw upon my vast knowledge of the pharma industry's recent hsitory to offer a more in-depth analysis of the causes. You might be surprised at what I think is a major factor in the sinking and subsequent recovery of pharma's public image.

Includes a nice chart showing Harris survey data trend from 1998 through 2006.

For more on this subject, see today's post to Pharma Marketing Blog.

Mike Pucci, Vice President of External Affairs at GlaxoSmithKline (GSK), is a man with a mission, which is to get the word out about the good that the pharmaceutical industry is doing (or, as Pucci expressed his goal: to "Restore the reputation of the industry by communicating the value of our products, our research and our hope for the future"). He spoke recently at an industry Forum on Customer Relationship Management (CRM) held in Princeton, New Jersey.

Topics covered include:

• Key Messages
• Genesis and Structure of the Grassroots Campaign
• Role of PhRMA
• Program Available from GSK